Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.

Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q33424781

about

Obinutuzumab for the treatment of indolent lymphoma Recent advances in therapy of chronic lymphocytic leukaemia.Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics

P2860

Q38818380-03B1798A-F804-4E56-9544-98F6DCE3ACB2 Q38862525-108A8B08-4790-4BBB-B38F-D295BF45DF3A Q56594845-F9BD102F-CD03-4519-B07D-A958CD6BC71B

P2860

Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q33424781

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Fludarabine, cyclophosphamide, ...... chronic lymphocytic leukemia.

@ast

Fludarabine, cyclophosphamide, ...... chronic lymphocytic leukemia.

@en

type

label

Fludarabine, cyclophosphamide, ...... chronic lymphocytic leukemia.

@ast

Fludarabine, cyclophosphamide, ...... chronic lymphocytic leukemia.

@en

prefLabel

Fludarabine, cyclophosphamide, ...... chronic lymphocytic leukemia.

@ast

Fludarabine, cyclophosphamide, ...... chronic lymphocytic leukemia.

@en

P1433

Q33424781-6E425857-A166-4BEC-BFD8-65F43FC37D2A

P1476

Q33424781-DEFCCD25-2FD3-48D0-ABBC-A85AF7A4A934

P2093

Q33424781-ADB8BD96-54ED-4212-A66B-122D06B83139

Q33424781-BA9BCCF0-1639-45C7-BAA3-6E287BDA28B5

P2860

Q33424781-039016A9-D0BA-4E9D-B7F0-18733E4905C4

Q33424781-08A99D5B-DE48-4E5C-9738-3025B3C86AB9

Q33424781-1A3C31FC-1428-4ADC-9DE9-86B385D8F867

Q33424781-28AF79C7-38A8-4940-9DC5-4C82C153701C

Q33424781-4E7361F6-6FE7-4477-B35E-43B2D6002EF8

Q33424781-6AB5AAB3-9F00-4D51-9812-5730CED21C43

Q33424781-6B6CBADE-956A-4FF4-8D81-1AABB7E1F16F

Q33424781-797039AD-EBE5-4B3C-942A-A5AF6BA8C6D4

Q33424781-7A30D6C4-70FB-46DC-9935-F81C2609B417

Q33424781-92966540-EAF3-41CF-A59B-1450BBE459B2

P304

Q33424781-4982DD3C-E748-4A2F-8D70-6FDFCF57D718

P31

Q33424781-F4EC4520-8F7E-44E5-A911-405407612A57

P356

Q33424781-D2D86197-4757-41F3-B489-7C17F4E7FA09

P407

Q33424781-07E28169-222B-4E96-B6F2-9C9DCA0FF815

P433

Q33424781-FE9125FE-7167-491E-BF47-C03A7FC5515F

P478

Q33424781-0D11A70A-BF56-4200-994B-FBE1689F2D9E

P50

Q33424781-24A32AAC-9B1F-4E03-851B-554DF7301C62

Q33424781-5F46331B-23E1-460B-88DF-9DD65CCA1D3B

Q33424781-991FF0A8-0891-46D4-8CD8-54E15344E478

Q33424781-B86C728D-DF85-4052-96CF-8FABB1C98ED4

Q33424781-B982579F-DF76-4D8F-9A38-53D1B6A460B4

Q33424781-D0BE1D8E-FEEA-45E2-AF24-C505B71BB4D5

P577

Q33424781-A565FBA3-9EE3-425C-BE82-0EDA90C53A9A

P698

Q33424781-142196FD-AACD-4670-9078-9E084A6FA1E0

P921

Q33424781-155024A7-04C4-4BDA-B7D4-2D80F55607B6

Q33424781-EE033073-BB38-495E-B8F5-0781DD4FBD5E

P932

Q33424781-D62E8B42-DE7E-4F53-BA21-66B3FA15B879

P356

P1433

P1476

Fludarabine, cyclophosphamide, ...... chronic lymphocytic leukemia.

@en

P2093

Susan C Smith

http://www.w3.org/2001/XMLSchema#string

Susan M O'Brien

http://www.w3.org/2001/XMLSchema#string

P2860

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression

Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.

P304

3869-3876

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.29605

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas J. Short

Alessandra Ferrajoli

William G Wierda

Michael J. Keating

P577

2015-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26218678

http://www.w3.org/2001/XMLSchema#string

P921

P932

4824541

http://www.w3.org/2001/XMLSchema#string